/
ACTU
$0.98+$0.01 (+0.54%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$23.2M
24M shares
52-week range
$0.91 – $9.22
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-7.63
Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
www.actuatetherapeutics.com- Employees
- 12
- IPO / List date
- Aug 13, 2024
- HQ
- FORT WORTH, TX
Held by traders on TradeandTell
No one on the platform currently holds ACTU.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ACTU as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ACTU yet.
